Transforming treatment outcomes for solid cancers

Focus

Sources:
1) https://seer.cancer.gov/statfacts/html/all.html
2) T. N. Seyfried and L.C. Huysentruyt, Crit Rev Oncog. 2013; 18(1-2): 43–73.
3) https://www.aacr.org/about-the-aacr/newsroom/news-releases/cancer-care-costs-in-the-united-states-are-projected-to-exceed-245-billion-by-2030/

Triple Negative Breast Cancer (TNBC)

Initial Addressable Market: Every year in the U.S. there are nearly 300,000 new cases of female breast cancer with over 40,000 being Triple-Negative Breast Cancer (TNBC), an area of high unmet medical need

1) TNBC is the most difficult type of breast cancer to treat

2) Has a high rate of recurrence within 3 years with residual cancer burden

3) A 5-year survival rate with distant metastases of only 12%

4) Accounts for 40% of all breast cancer-related mortality

Sources:
1) A. N. Giaquinto et. al., CA CANCER J CLIN 2022;72:524-541
2) R. L. Stewart et. al., Cancer Res. 2019; 79:3466–3478
3) https://www.cancer.org/cancer/breast-cancer.html (2022)
4) Q. Wu et. al., Cancers 2021; 13: 3697

Sample TNBC Patient Journey

Solutions

EMBioSys develops non-pharmacological, non-toxic, electrode-free wearable garments to deliver therapeutic induced Electric Fields (iEF Therapy) to potentiate the standard of care.  Our wearable garments are deployed for patient use at home.
iEF Therapy treatment outcomes:
  • Hinder Metastasis
  • Reduce tumor volume & weight
  • Improve efficacy of chemotherapy
  • Improve host immune response
  • Selectively target only cancer cells
  • Have no adverse effects
Breast Cancer camisole garment example shown below

iEF Therapy Data

Pulmonary metastases are reduced

(in vivo  – 4T1 model)

Tumor volume and weight are reduced

(in vivo  – 4T1 model)

Source: Induced electric fields inhibit breast cancer growth and metastasis by modulating the immune tumor microenvironment; https://biorxiv.org/cgi/content/short/2024.04.14.589256v1

iEF Science

EMBioSys’ iEF therapy works both at the cellular level targeting only cancer cells, and at the tissue, organ, and organism levels using a 4-pronged approach:

1) iEFs alter the cancer cell’s cytoskeleton making it unable to move

2) iEFs deprives cells of much-needed energy to move and proliferate

3) iEFs reverse epithelial-to-mesenchymal transition (EMT) preventing detachment

4) iEFs enhance immune response by attracting anti-tumor immune cells and dissuading pro-tumor immune cells both at primary and metastatic sites

Publications

Title: Induced electric fields inhibit breast cancer growth and metastasis by modulating the immune tumor microenvironment

Download
Authors: Manish Charan, Travis H. Jones, Dinesh K. Ahirwar, Nandini Acharya, Vish V. Subramaniam, Ramesh K Ganju, and Jonathan W Song

Title: Directional Migration of Breast Cancer Cells Hindered by Induced Electric Fields May Be Due to Accompanying Alteration of Metabolic Activity

Download
Authors: Travis H. Jones, PhD,  Kirti Kaul, PhD,  Ayush A. Garg, PhD,  Jonathan W. Song, PhD,  Ramesh K. Ganju, PhD,  and Vish V. Subramaniam, PhD

Title: Electromagnetic fields alter the motility of metastatic breast cancer cells

Download
Authors: Ayush Arpit Garg, Travis H. Jones, Sarah M. Moss, Sanjay Mishra, Kirti Kaul, Dinesh K. Ahirwar, Jessica Ferree, Prabhat Kumar, Deepa Subramaniam, Ramesh K. Ganju, Vish V. Subramaniam & Jonathan W. Song

Title: Non-contact method for directing electrotaxis

Download
Authors: Dinesh K. Ahirwar, Mohd W. Nasser, Travis H. Jones, Emily K. Sequin, Joseph D. West, Timothy L. Henthorne, Joshua Javor, Aniruddha M. Kaushik, Ramesh K. Ganju & Vish V. Subramaniam

Related Publications

Title: Evaluation of electrical properties of ex vivo human hepatic tissue with metastatic colorectal cancer

Download
Authors: Varun Lochab, Travis H Jones1, Emily Alkandry1, Joseph D West1, Mohamed H Abdel-Rahman2, Vish V Subramaniam, and Shaurya Prakash

Title: Ex vivo electrical impedance measurements on excised hepatic tissue from human patients with metastatic colorectal cancer

Download
Authors: S. Prakash, M. P. Karnes, E. K. Sequin, J. D. West, C. L. Hitchcock, S. D. Nichols, M. Bloomston, S. R. Abdel-Misih, C. R. Schmidt, E. W. Martin Jr, S. P. Povoski, and V. V. Subramaniam

News

09/11/2024

EMBioSys is honored to announce that our President and Chief Scientific Officer, Dr. Vish Subramaniam, has been asked to present at the Cancer Bioelectricity Conference sponsored by the National Cancer Institute on September 12th, 2024. 

Dr. Subramaniam will be speaking about “Technologies for treatment of Metastatic Solid Tumors”, including EMBioSys’ iEF Therapy.  One of the key goals of the conference is to disseminate the science of bioelectricity and its potential applications towards cancer treatments to a diverse audience.  The National Cancer Institute’s support for research and development of bioelectricity is an important step in the evolution of life-saving technologies for cancer patients in the future.

Link to the event site and agenda: https://cam.cancer.gov/news_and_events/conferences.htm

08/21/2024

EMBioSys is excited to be selected among the first 100 Innovators to present at LSI USA, March 17th – 21st, 2025!  Looking forward to the event!

07/01/2024

EMBioSys is pleased to announce that Tracey Wielinski has joined our Advisory Board. Tracey is a Regulatory, Clinical and Quality executive with 30 years of experience in the Medical Device and Pharmaceutical space focused on strategic, global product realization and compliant business processes. We are looking forward to having Tracey on the team to advise us, as we move towards clinical trials.

06/25/2024

We are excited to announce that Rick Clemon has joined our Advisory Board!

Rick is a CFO with 30 years of experience spanning diverse sectors, including development and clinical-stage life science and medical device companies advancing research and development across pharmaceuticals, biologics, therapies, and assistive technologies focused on cancers, retinal disease, and kidney disease. Rick’s wisdom, enthusiasm, and passion for our mission will surely be a tremendous asset as EMBioSys moves towards clinical trials in humans.

06/18/2024

We are honored to announce that Silvia C. Formenti, MD has joined our Advisory Board!

Dr. Formenti is Chair of the Department of Radiation Oncology at Weill Cornell Medicine, and Radiation Oncologist-in-Chief at NewYork-Presbyterian Hospital. She is a recognized leader in cancer research, experienced in translating preclinical work into clinical trials in metastatic breast cancer, lung cancer, and melanoma.

05/09/2024

EMBioSys is excited to announce that we have received a Small Business Innovation Research (SBIR) Phase 1 Award from the National Cancer Institute for Development of a Wearable, Non-invasive, Treatment Device for Metastatic Triple-Negative Breast Cancer (TNBC). We are grateful to the NIH/NCI in recognizing the potential of our therapeutic induced electric field (iEF) technology towards improving treatment outcomes and potentiating standard of care for treatment of solid metastatic cancers.

We look forward to collaborating with our research partners at The Ohio State University on this award.

04/30/2024

We are honored to announce that Joe Camardo, MD has officially joined EMBioSys as a Medical Advisor. Joe is a Board Certified General Internist with 30 years of drug development experience in multiple areas, including oncology, inflammation, vaccines, neuroscience, and roles as head of clinical research and medical affairs.

Since our iEF therapy potentiates standard of care including chemotherapy, Joe’s experience will surely help us navigate the fastest path to market, and saving lives.

02/01/2024

We are trilled to announce that Jennifer Herron has joined EMBioSys as an Independent Board Director and Strategic Advisor! Jennifer’s dedication to our mission is humbling, and we are grateful for her guidance and passion.

Leadership

Chris Barron

Co-Founder & Chief Executive Officer

Vish Subramaniam, PhD

Co-Founder, President & Chief Scientific Officer

Jennifer Herron

Independent Board Member & Strategic Advisor

Advisory Board

Joe Camardo, MD

Board Certified General Internist with 30 years of drug development experience in multiple areas, including oncology, inflammation, vaccines, neuroscience, and roles as head of clinical research and medical affairs

Silvia C. Formenti, MD

Chair of the Department of Radiation Oncology at Weill Cornell Medicine, and Radiation Oncologist-in-Chief at NewYork-Presbyterian Hospital; A recognized leader in cancer research, experienced in translating preclinical work into clinical trials in metastatic breast cancer, lung cancer, and melanoma

Rick Clemon, CPA, CGMA

CFO with 30 years of experience spanning diverse sectors, including development and clinical-stage life science and medical device companies advancing research and development across pharmaceuticals, biologics, therapies, and assistive technologies focused on cancers, retinal disease, and kidney disease

Tracey Wielinski

Regulatory, Clinical and Quality executive with 30 years of experience in the Medical Device and Pharmaceutical space focused on strategic, global product realization and compliant business processes

Our Mission

To commercialize novel, non-invasive, and effective electromagnetic treatments for metastatic cancer that improve patient quality of life, standard of care, and overall treatment outcomes

Our Vision

To aid in the realization of a future whereby treatment of metastatic cancer is no longer associated with harsh side effects, financial disparity, and shortened life expectancy

Our Products

Home-Use, Non-pharmacological, electrode-free wearable garments that hinder solid cancer metastasis, while improving the efficacy of standard of care therapies

Contact Us

    © 2024 EMBioSys Inc. All rights reserved.